Theravance Biopharma Inc (TBPH)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $884.18M
Last updated: Nov 06, 2026 at 4:00 PM ET
Theravance Biopharma Inc (TBPH) Financials: Revenue, Profit and Cash Flow
Theravance Biopharma reported revenue of $107.46M for the fiscal year ended Dec 31, 2025, up 66.9% from the year before. That year, net income was $105.89M with a net margin of 98.5%, operating cash flow was $238.54M and free cash flow was $238.50M. The quarter ended Jun 30, 2026 had revenue of $20.73M and net income of -$5.90M.
Revenue and Margins
The operating margin was -3.4% in the fiscal year ended Dec 2025, the highest of the 3 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $48.65M, a compound annual rate of 9.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $107.46M | +66.9% | 100.0% | -3.4% | 98.5% |
| Dec 2024 | $64.38M | +12.1% | 100.0% | -72.9% | -87.6% |
| Dec 2023 | $57.42M | +11.8% | 100.0% | -97.6% | -96.1% |
| Dec 2022 | $51.35M | -7.2% | 100.0% | -179.1% | 1698.5% |
| Dec 2021 | $55.31M | -23.0% | 100.0% | -466.1% | -360.6% |
| Dec 2020 | $71.86M | -2.1% | 100.0% | -414.2% | -386.9% |
| Dec 2019 | $73.41M | +21.6% | 100.0% | -343.1% | -322.1% |
| Dec 2018 | $60.37M | +292.4% | 98.8% | -395.5% | -357.0% |
| Dec 2017 | $15.39M | -68.4% | 60.8% | -1690.6% | -1855.0% |
| Dec 2016 | $48.65M | N/A | 94.1% | -371.0% | -391.9% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Jun 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $107.46M | $64.38M | $57.42M | $51.35M | $55.31M | $71.86M | $73.41M | $60.37M | $15.39M | $48.65M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $715.00K | $6.03M | $2.89M |
| Gross profit | $107.46M | $64.38M | $57.42M | $51.35M | $55.31M | $71.86M | $73.41M | $59.66M | $9.36M | $45.75M |
| Research and development | $37.41M | $37.64M | $40.62M | $63.39M | $193.66M | $260.95M | $219.25M | $201.35M | $173.89M | $141.71M |
| Operating income | -$3.60M | -$46.95M | -$56.03M | -$91.96M | -$257.78M | -$297.63M | -$251.91M | -$238.75M | -$260.12M | -$180.47M |
| Net income | $105.89M | -$56.42M | -$55.19M | $872.13M | -$199.43M | -$278.02M | -$236.46M | -$215.52M | -$285.40M | -$190.67M |
| EBITDA | $84.52M | -$38.45M | -$42.66M | -$75.71M | -$248.09M | -$286.75M | -$237.31M | -$222.30M | -$251.53M | -$176.04M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.73M | $17.70M | $45.89M | $19.99M | $26.20M | $15.39M | $18.75M | $16.87M | $14.26M | $14.50M | $17.57M | $15.69M |
| Gross profit | $20.73M | $17.70M | $45.89M | $19.99M | $26.20M | $15.39M | $18.75M | $16.87M | $14.26M | $14.50M | $17.57M | $15.69M |
| Operating income | -$8.28M | -$9.48M | $20.01M | -$6.46M | -$2.73M | -$14.43M | -$9.20M | -$10.84M | -$15.71M | -$11.21M | -$6.24M | -$8.76M |
| Net income | -$5.90M | -$4.93M | $61.02M | $3.62M | $54.84M | -$13.58M | -$15.53M | -$12.70M | -$16.53M | -$11.66M | -$8.51M | -$8.95M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $10.95M by $156.86M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $485.57M | $354.16M | $382.00M | $607.40M | $374.82M | $469.06M | $408.83M | $560.24M | $441.40M | $639.25M |
| Current assets | $418.46M | $161.07M | $133.54M | $353.46M | $249.87M | $393.34M | $338.49M | $532.82M | $378.75M | $528.50M |
| Cash and equivalents | $167.81M | $37.80M | $39.55M | $298.17M | $89.96M | $81.47M | $58.06M | $378.02M | $88.98M | $344.71M |
| Total liabilities | $188.85M | $178.62M | $169.00M | $165.60M | $713.39M | $772.81M | $632.67M | $611.82M | $326.22M | $289.02M |
| Short-term debt | $10.95M | $10.71M | $3.92M | $6.75M | $16.94M | $19.33M | $9.85M | N/A | $223.75M | $222.68M |
| Long-term debt | N/A | N/A | N/A | N/A | $228.03M | $226.96M | $225.89M | $224.82M | $223.75M | $222.68M |
| Shareholder equity | $296.72M | $175.54M | $213.00M | $441.80M | -$338.57M | -$303.75M | -$223.84M | -$51.59M | $115.18M | $350.23M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $469.77M | $472.31M | $485.57M | $415.46M | $426.04M | $343.58M | $354.16M | $356.11M | $362.03M | $371.31M | $382.00M | $413.59M |
| Total liabilities | $180.06M | $181.72M | $188.85M | $182.78M | $201.19M | $177.60M | $178.62M | $170.45M | $168.34M | $166.44M | $169.00M | $167.46M |
| Cash and equivalents | $219.77M | $288.10M | $167.81M | $174.77M | $281.93M | $110.61M | $37.80M | $23.38M | $46.34M | $53.84M | $39.55M | $71.69M |
| Shareholder equity | $289.70M | $290.59M | $296.72M | $232.68M | $224.85M | $165.98M | $175.54M | $185.65M | $193.69M | $204.87M | $213.00M | $246.13M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 100.0% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $238.54M | -$11.54M | -$27.00M | -$186.99M | -$207.86M | -$250.40M | -$238.20M | -$112.87M | -$201.05M | -$98.99M |
| Capital expenditures | $42.00K | $332.00K | $2.49M | $572.00K | $3.41M | $6.62M | $3.18M | $7.24M | $2.41M | $2.13M |
| Free cash flow | $238.50M | -$11.87M | -$29.48M | -$187.56M | -$211.26M | -$257.02M | -$241.37M | -$120.11M | -$203.46M | -$101.12M |
| Dividends paid | N/A | N/A | N/A | $802.00K | N/A | $385.06M | N/A | N/A | $0 | $0 |
| Share repurchases | $0 | $445.00K | $197.05M | $128.83M | $0 | $0 | N/A | N/A | N/A | N/A |
| Investing cash flow | -$105.28M | $12.28M | -$32.70M | $1.15B | $124.49M | $10.72M | -$83.05M | $176.71M | -$56.33M | -$148.24M |
| Financing cash flow | -$3.25M | -$2.50M | -$198.93M | -$758.81M | $91.86M | $263.08M | $1.29M | $225.20M | $1.66M | $479.23M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.96M | $73.28M | -$6.06M | -$6.51M | $208.07M | $43.04M | -$902.00K | -$5.20M | -$4.42M | -$1.02M | -$854.00K | -$2.49M |
| Capital expenditures | N/A | $0 | $8.00K | $0 | $34.00K | $0 | $190.00K | $15.00K | $36.00K | $91.00K | $677.00K | $21.00K |
| Free cash flow | N/A | $73.28M | -$6.07M | -$6.51M | $208.04M | $43.04M | -$1.09M | -$5.21M | -$4.45M | -$1.11M | -$1.53M | -$2.51M |
Frequently Asked Questions About TBPH
What is Theravance Biopharma's annual revenue?
Theravance Biopharma reported revenue of $107.46M for the fiscal year ended Dec 31, 2025.
How fast is Theravance Biopharma's revenue growing?
Revenue was up 66.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 27.9%.
Is Theravance Biopharma profitable?
Yes. Theravance Biopharma reported net income of $105.89M for the fiscal year ended Dec 31, 2025, with a net margin of 98.5%.
How much free cash flow does TBPH generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $238.54M minus capital expenditures of $42.00K produced free cash flow of $238.50M.
How much debt does Theravance Biopharma have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $10.95M and cash and equivalents of $167.81M.
TBPH pages: Overview, Financials